EC approves Keytruda regimen for triple-negative breast cancer
Approval covers patients with locally recurrent or metastatic TNBC
Read More
Tag: triple-negative breast cancer
Roche withdraws US approval for Tecentriq in mTNBC
Metastatic triple-negative breast cancer treatment failed to meet PFS primary endpoint
Read More
Researchers identify existing drug’s potential for triple negative breast cancer
Study suggests that palbociclib could be used to treat around a fifth of people with TNBC
Read More
Roche’s Tecentriq shows promise in early triple-negative breast cancer
Less patients who received the Tecentriq combination before surgery had evidence of tumour tissue detectable at the time of surgery
Read More
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
The results showed a 73% overall response rate irrespective of PD-L1 status.
Read More
Researchers discover ‘new line of attack’ on triple negative breast cancer
Scientists have uncovered a novel approach to fighting hard-to-treat breast cancers, triggering a new drug programme designed to develop novel targeted therapies for the disease.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
